Mid-Atlantic BioTherapeutics is pleased to share that Dr. Debanu Das will serve as a panelist in the upcoming event, “Outsourcing Science: How to Choose, Manage, and Learn from CROs and CRDMOs,” taking place on August 5, 2026.
As outsourcing continues to play a critical role in accelerating drug discovery and development, this panel will bring together industry leaders to discuss best practices in selecting and managing contract research and development partners. The conversation will also explore how organizations can extract maximum scientific and operational value from these collaborations.
Dr. Das will contribute his perspective on building effective CRO relationships, with an emphasis on aligning scientific rigor, communication, and execution to support high-impact programs. His experience in advancing complex preclinical initiatives and managing external partnerships will provide practical insights for biotech and pharmaceutical teams navigating outsourced research models.
The session is expected to cover key themes including partner selection criteria, governance structures, data quality oversight, and lessons learned from both successful and challenging engagements.
Event details and registration are available here: https://luma.com/7uwt2csz?mc_cid=7723373c78&mc_eid=80d141d26d
Debanu Das, PhD, is the Co-Founder and CEO of Accelero Biostructures and Co-Founder of XPose Therapeutics, where he pioneered a structure-first approach to drugging traditionally “undruggable” targets, using 3D crystal structures of small molecules bound to DNA Damage Response (DDR) proteins to generate novel therapeutic leads. This DDR-focused pipeline supports multiple treatment strategies, including enzyme inhibition, synthetic lethality, and targeted-protein degradation. XPose’s discovery was powered by Accelero’s high-throughput protein X-ray crystallography platforms, which enabled rapid fragment screening and iterative, structure-guided optimization of hit compounds. In 2026, XPose was acquired by Mid-Atlantic BioTherapeutics (MABT). Debanu joined MABT’s leadership team as part of the acquisition, bringing over 20 years of expertise in structural biology, drug discovery and outsourced R&D with CROs. Debanu holds a PhD from Rutgers-The State University of New Jersey, New Brunswick, and an Integrated MS from the Indian Institute of Technology, Kanpur.